Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > BCYC down 33% pre market

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Apr 11, 2022 12:53pm

110 Views

Post# 34594141

RE:RE:RE:RE:BCYC down 33% pre market

This is the nature of early data. You are making broad stroke assessments and things quickly shift with each new piece of the puzzle. That's how it goes until you have enough data to get a true picture of where it will all land. I'm with you, their data looks ok. Maybe the stock will end up about where it was prior to the recent volitility, all seems like an over-reaction.

It will be interesting to see who are the winners and losers from AACR. My guess is THTX will be largely unnoticed.

Wino115 wrote: So rises on it's COVID therapy last week, falls on overly optimistic projections on it's Nectin-3 oncology. Nervous market and indecisive investors. I don't follow it that closely so don't know what the AACR expectations were, but the overall results seemed ok -- ORR around 50% and a mixture of responses. Safety actually looked ok. Guess the market just wanted more from it. I suppose a reason to always keep expectations on the low side!

qwerty22 wrote:
Some commentary

https://endpts.com/the-one-early-biotech-bright-spot-at-aacr22-just-turned-red/

palinc2000 wrote: Bicycle Therapeutics down 33% after rising sharply on Friday on bladder cancer data
https://seekingalpha.com/news/3822312-bicycle-therapeutics-down-significantly-after-rising-sharply-on-friday-on-bladder-cancer-data?source=copyToPasteboard